Table 3.
Characteristic | Patients, No. (%) [95% CI]b | P Value | ||
---|---|---|---|---|
All (N = 8038) |
RWHAP Funded (n = 6013) |
Non-RWHAP Funded (n = 2025) |
||
Total | 6013 (72.8) [67.7–77.9] | 2025 (27.2) [22.1–32.3] | ||
Age, y | ||||
18–29 | 596 (7.5) [6.7–8.4] | 503 (8.5) [7.4–9.5] | 93 (5.0) [3.9–6.2] | <.001 |
30–39 | 1293 (16.7) [15.5–17.9] | 1026 (17.9) [16.5–19.3] | 267 (13.6) [12.0–15.2] | |
40–49 | 2940 (36.0) [34.6–37.3] | 2180 (35.3) [33.7–37.0] | 760 (37.8) [35.5–40.1] | |
≥50 | 3209 (39.8) [38.5–41.1] | 2304 (38.3) [36.7–40.0] | 905 (43.6) [40.6–46.6] | |
Sex | ||||
Male | 5764 (71.7) [69.7–73.8] | 4130 (69.0) [67.0–71.0] | 1634 (79.0) [75.9–82.2] | <.001 |
Female | 2152 (26.7) [24.7–28.7] | 1782 (29.2) [27.2–31.2] | 370 (20.1) [17.0–23.1] | |
Transgender | 120 (1.5) [1.2–1.9] | 99 (1.8) [1.4–2.2] | 21 (0.9) [0.5–1.3] | |
Sexual transmission risk categoryc | ||||
Any MSM | 3733 (47.4) [44.0–50.9] | 2389 (41.0) [37.5–44.6] | 1344 (64.6) [60.3–68.8] | <.001 |
MSW only | 1980 (23.6) [21.6–25.6] | 1703 (27.2) [25.0–29.5] | 277 (13.8) [11.8–15.8] | |
Any WSM | 2100 (26.0) [24.1–27.9] | 1736 (28.4) [26.5–30.2] | 364 (19.7) [16.7–22.8] | |
Other | 225 (2.9) [2.4–3.4] | 185 (3.3) [2.7–4.0] | 40 (1.9) [1.2–2.5] | |
Race/ethnicity | ||||
White, non-Hispanic | 2560 (33.5) [29.4–37.7] | 1387 (25.3) [22.2–28.4] | 1173 (55.6) [49.6–61.5] | <.001 |
Black, non-Hispanic | 3316 (41.6) [35.9–47.2] | 2831 (47.5) [41.5–53.5] | 485 (25.8) [20.6–31.0] | |
Hispanic or Latino | 1775 (19.9) [15.5–24.2] | 1521 (22.5) [16.4–28.6] | 254 (12.9) [10.6–15.2] | |
Otherd | 387 (5.0) [4.2–5.8] | 274 (4.8) [3.8–5.7] | 113 (5.8) [4.7–6.8] | |
Born outside the United States | 1033 (13.3) [11.6–14.9] | 851 (14.7) [12.4–17.0] | 182 (9.5) [7.9–11.1] | .001 |
Educational attainment | ||||
<High school | 1824 (22.0) [20.1–23.9] | 1615 (26.1) [24.0–28.3] | 209 (10.9) [8.7–13.1] | <.001 |
High school diploma or equivalent | 2206 (27.2) [25.4–29.0] | 1798 (29.5) [27.6–31.4] | 408 (21.1) [18.2–24.1] | |
>High school | 4007 (50.8) [47.8–53.7] | 2599 (44.4) [41.7–47.0] | 1408 (68.0) [63.5–72.4] | |
At or below poverty levele,f | 3665 (45.4) [42.3–48.5] | 3212 (53.6) [50.3–56.9] | 453 (23.9) [19.7–28.0] | <.001 |
Health insurance coverage during the past 12 moe,g | ||||
Continuous | 5768 (70.8) [67.9–73.8] | 4014 (65.0) [61.8–68.1] | 1754 (86.5) [84.1–88.9] | <.001 |
Lapsed | 767 (9.3) [8.4–10.3] | 620 (10.0) [8.8–11.2] | 147 (7.4) [5.8–9.0] | |
None | 1480 (19.8) [16.9–22.8] | 1358 (25.0) [21.9–28.1] | 122 (6.1) [4.1–8.0] | |
Past 12-mo statuse | ||||
Homeless | 716 (8.5) [7.6–9.4] | 626 (9.9) [8.7–11.1] | 90 (4.8) [3.7–5.9] | <.001 |
Incarcerated | 428 (5.4) [4.7–6.0] | 375 (6.4) [5.6–7.2] | 53 (2.7) [1.6–3.8] | <.001 |
Noninjection drug use | 2117 (26.7) [25.1–28.2] | 1518 (25.6) [23.9–27.3] | 599 (29.6) [27.3–31.9] | .003 |
Injection drug use | 215 (2.5) [1.8–3.2] | 172 (2.6) [1.8–3.3] | 43 (2.2) [1.3–3.2] | .47 |
Binge alcohol use in the past 30 d | 1325 (16.3) [15.4–17.3] | 984 (16.1) [14.9–17.3] | 341 (16.9) [15.1–18.7] | .47 |
Time since HIV diagnosis, y | ||||
<5 | 1738 (22.7) [21.5–24.0] | 1392 (24.3) [22.7–25.9] | 346 (18.6) [16.6–20.6] | <.001 |
5–9 | 1772 (21.8) [20.9–22.8] | 1350 (22.0) [20.9–23.2] | 422 (21.2) [19.2–23.2] | |
≥10 | 4521 (55.4) [54.0–56.9] | 4240 (53.7) [51.8–55.5] | 1252 (60.2) [57.6–62.9] | |
Disease stageh | ||||
AIDS or nadir CD4+ 0–199 cells/µL or CD4+ <14% | 5555 (68.5) [67.0–70.0] | 4240 (69.7) [68.0–71.4] | 1315 (65.2) [62.8–67.5] | <.001 |
No AIDS and nadir CD4+ 200 to 499 cells/µL or CD4+ 14% to <29% |
1931 (24.9) [23.6–26.3] | 1401 (24.2) [22.7–25.7] | 530 (26.8) [24.5–29.1] | |
No AIDS and nadir CD4+ ≥500 cells/µL or CD4+ ≥29% | 516 (6.6) [5.9–7.3] | 350 (6.1) [5.3–6.8] | 166 (8.0) [6.9–9.2] | |
Depression in the past 2 wk | ||||
Major | 873 (11.1) [9.9–12.3] | 669 (11.3) [10.0–12.6] | 204 (10.5) [8.3–12.8] | .007 |
Other | 964 (12.7) [11.6–13.7] | 769 (13.6) [12.3–14.8] | 195 (10.3) [8.7–11.9] | |
Prescribed ART in the past 12 moe,i | 7269 (90.6) [89.5–91.7] | 5423 (90.4) [89.1–91.7] | 1846 (91.0) [89.4–92.6] | .53 |
Viral suppressionj | 3165 (75.5) [73.4–77.6] | 2397 (74.4) [72.0–76.8] | 768 (79.0) [75.9–82.2] | .02 |
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; MSM, men who have sex with men whether or not they also reported sex with women; MSW, men who have sex with women only; RWHAP, Ryan White HIV/AIDS Program; WSM, women who have sex with men whether or not they also reported sex with women.
Data presented No. (%) are sample size (weighted percentage). Facility and patient data were weighted based on known probabilities of selection and adjusted for nonresponse using predictors of facility-level and patient-level response. The sample design and weighting methods allow inference to all outpatient HIV health care facilities providing care and HIV-infected persons receiving care in the United States during the first 4 months of the cycle year (2009 and 2011).
Participants who reported no anal, vaginal, or oral sex in the past 12 months were categorized according to self-reported sexual orientation.
Includes Asian, American Indian, Alaska native, Native Hawaiian, Other Pacific Islander, and multiracial groups.
During the 1-year period preceding the interview (2009 data were collected in interviews conducted between June 2009 and May 2010; 2011 data were collected in interviews conducted between June 2011 and May 2012).
Determined using the US Department of Health and Human Services poverty guidelines.16
Having health insurance or coverage does not include having only RWHAP assistance.
AIDS was defined as confirmed HIV infection with either: a CD4+ T-lymphocyte cell count less than 200 cells/µL, a CD4+ T-lymphocyte cell percentage of total lymphocytes less than 14%, or a diagnosis of a stage 3–defining opportunistic illness.
Documentation in the medical record of prescription of antiretroviral therapy.
Documentation in the medical record of the most recent viral load being undetectable or less than 200 copies/mL.